Endometrial Cancer Clinical Trials

A listing of 105 Endometrial Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Endometrial Cancer

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 105 active clinical trials seeking participants for Endometrial Cancer research studies. The states with the highest number of trials for Endometrial Cancer participants are Texas, New York, California and Ohio.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer

NCT04586959

Recruiting

This is a prospective, multi-center, randomized non-inferiority phase III study to evaluate if patients undergoing a minimally invasive surgery for early stage uterine cancer have cancer cells in the fluid that is obtained at the time of their surgery when a uterine manipulator is placed versus patients who do not have a uterine manipulator placed.

Gender:

FEMALE

Ages:

Between 18 years and 90 years

Trial Updated:

12/18/2024

Locations: Cleveland Clinic, Cleveland, Ohio +4 locations

Conditions: ENDOMETRIAL CANCER

Learn More ›

Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer

NCT04458402

Recruiting

Studying adjuvant hypofractionated whole pelvis radiation therapy in Endometrial Cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

08/27/2024

Locations: University of Cincinnati Medical Center, Cincinnati, Ohio

Conditions: Endometrial Cancer

Learn More ›

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478

Recruiting

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancerovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/25/2025

Locations: City of Hope, Duarte, California +56 locations

City of Hope, Duarte, California

Yale Cancer Center, New Haven, Connecticut

Washington University, School of Medicine, Saint Louis, Missouri

Roswell Park Cancer Institute IDS, Buffalo, New York

Memorial Sloan Kettering Hospital, New York, New York

SCRI Oncology Partners, Nashville, Tennessee

The University of Texas MD Anderson Cancer Center, Houston, Texas

Chris O'Brien Lifehouse, Camperdown, Not set

Icon Cancer Centre Chermside, Chermside, Not set

Monash Medical Centre Clayton, Clayton, Not set

Icon Cancer Centre Hobart, Hobart, Not set

Icon Cancer Centre Townsville, Hyde Park, Not set

Cliniques Universitaires Saint-Luc, Bruxelles, Not set

UZA, Edegem, Not set

Universitair Ziekenhuis Gent, Gent, Not set

Universitair Ziekenhuis Brussel, Jette, Not set

UZ Leuven, Leuven, Not set

Chu Bordeaux, Bordeaux, Not set

Centre Georges Franăois Leclerc, Dijon, Not set

Hopital Claude Huriez - Chu Lille, Lille, Not set

Centre Léon Bérard, Lyon, Not set

Hăpital de La Timone, Marseille, Not set

Chu Nantes - Hătel Dieu, Nantes, Not set

Institut Claudius Regaud, Toulouse, Not set

Institut Gustave Roussy, Villejuif, Not set

Saitama Medical University International Medical Center, Hidaka, Not set

National Cancer Center Hospital East, Kashiwa-shi, Not set

NHO Shikoku Cancer Center, Matsuyama-shi, Not set

Aichi Cancer Center Hospital, Nagoya, Not set

Kindai University Hospital, Osakasayama-shi, Not set

Shizuoka Cancer Center, Sunto-gun, Not set

National Cancer Center Hospital, Tokyo, Not set

Cancer Institute Hospital of JFCR, Tokyo, Not set

Yokohama City University Medical Center, Yokohama, Not set

Cha Bundang Medical Center, Cha University, Seongnam, Not set

Seoul National University Bundang Hospital, Seongnam, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Hospital Universitari Vall D'Hebron, Barcelona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital de La Santa Creu I Sant Pau, Barcelona, Not set

Hospital General Universitario Gregorio Marañon, Madrid, Not set

Hospital Universitario Ramon Y Cajal, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

HOSPITAL REGIONAL UNIVERSITARIO de MALAGA AVDA., Málaga, Not set

Hospital Universitario Virgen Macarena, Sevilla, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Chang Gung Memorial Hospital, Taoyuan, Not set

University Hospital Coventry, Coventry, Not set

Barts Hospital, London, Not set

Royal Free Hospital, London, Not set

Conditions: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer

Learn More ›

Use of an Intrauterine Manipulator and Its Correlation with Positive Peritoneal Cytology in Early Stage Endometrial Cancers

NCT04570553

Recruiting

This study aims to answer whether use of a Vcare® intrauterine manipulator leads to an increased incidence of positive peritoneal cytology in patients undergoing surgical management of early stage (FIGO stage I/II) endometrial cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/24/2025

Locations: Wellspan Health, York, Pennsylvania

Conditions: Endometrial Cancer

Learn More ›

Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer

NCT05850663

Recruiting

The purpose of this study is to examine the uses of a mobile health-based assessment and symptom monitoring platform.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/24/2025

Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma

Conditions: Head and Neck Cancer, Gynecologic Cancer, Cervical Cancer, Endometrial Cancer

Learn More ›

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958

Recruiting

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive MK-2870 sacituzumab tirumotecan live longer overall and without the cancer getting worse compared... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/21/2025

Locations: USA Mitchell Cancer Institute ( Site 4142), Mobile, Alabama +234 locations

USA Mitchell Cancer Institute ( Site 4142), Mobile, Alabama

Alaska Womens Cancer Care ( Site 4122), Anchorage, Alaska

HonorHealth (HH) ( Site 8000), Phoenix, Arizona

Arizona Oncology Associates - HOPE ( Site 8002), Tucson, Arizona

UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc, Los Angeles, California

California Pacific Medical Center - Van Ness Campus ( Site 4129), San Francisco, California

Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 4114), New Haven, Connecticut

MedStar Washington Hospital Center ( Site 4108), Washington, District of Columbia

Mount Sinai Cancer Center ( Site 4117), Miami Beach, Florida

AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 4113), Orlando, Florida

Florida Cancer Specialists - East ( Site 7000), West Palm Beach, Florida

Northside Hospital ( Site 4112), Atlanta, Georgia

Augusta University ( Site 4116), Augusta, Georgia

Centricity Research Columbus Cancer Center ( Site 4154), Columbus, Georgia

NorthShore University HealthSystem - Evanston Hospital ( Site 4110), Evanston, Illinois

Parkview Research Center at Parkview Regional Medical Center ( Site 4132), Fort Wayne, Indiana

Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 4150), Edgewood, Kentucky

University Medical Center New Orleans ( Site 4133), New Orleans, Louisiana

TRIALS 365 ( Site 4105), Shreveport, Louisiana

University of Massachusetts Memorial Medical Center ( Site 4103), Worcester, Massachusetts

Washington University School of Medicine-Obstetrics & Gynecology ( Site 4146), Saint Louis, Missouri

The Center of Hope ( Site 4109), Reno, Nevada

John Theurer Cancer Center at Hackensack University Medical Center ( Site 4118), Hackensack, New Jersey

Atlantic Health System Morristown Medical Center ( Site 4135), Morristown, New Jersey

Holy Name Medical Center ( Site 4115), Teaneck, New Jersey

New York - Presbyterian Brooklyn Methodist Hospital ( Site 4134), Brooklyn, New York

Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 4156), Mineola, New York

Laura and Isaac Perlmutter Cancer Center ( Site 4106), New York, New York

Icahn School of Medicine at Mount Sinai-Department of Obstetrics, Gynecology, and Reproductive Scie, New York, New York

Good Samaritan Hospital Medical Center ( Site 4139), West Islip, New York

Duke Cancer Institute ( Site 4120), Durham, North Carolina

Sanford Health Roger Maris Cancer Center ( Site 4158), Fargo, North Dakota

University of Cincinnati Medical Center ( Site 4136), Cincinnati, Ohio

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio

Sidney Kimmel Cancer Center - Jefferson Health ( Site 4157), Philadelphia, Pennsylvania

AHN West Penn Hospital-Gynecologic Oncology ( Site 4111), Pittsburgh, Pennsylvania

Asplundh Cancer Pavilion ( Site 4107), Willow Grove, Pennsylvania

Women & Infants Hospital ( Site 4138), Providence, Rhode Island

Sanford Cancer Center-Gynecologic Oncology ( Site 4121), Sioux Falls, South Dakota

The West Clinic, PLLC dba West Cancer Center ( Site 4102), Germantown, Tennessee

Houston Methodist Hospital-Obstetrics and Gynecology ( Site 4130), Houston, Texas

Texas Oncology - San Antonio ( Site 8005), San Antonio, Texas

Texas Oncology - Gulf Coast ( Site 8006), The Woodlands, Texas

Hospital Británico de Buenos Aires-Oncology ( Site 1002), Ciudad autónoma de Buenos Aires, Buenos Aires

Instituto Argentino de Diagnóstico y Tratamiento (IADT) ( Site 1008), Buenos Aires, Caba

Instituto Alexander Fleming-Alexander Fleming ( Site 1007), Ciudad Autónoma de Buenos Aires, Caba

Hospital Aleman-Oncology ( Site 1001), Buenos Aires, Not set

Instituto de Oncología Angel H. Roffo ( Site 1003), Buenos Aires, Not set

Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 1004), Buenos Aires, Not set

Fundación CORI para la Investigación y Prevención del Cáncer ( Site 1006), La Rioja, Not set

GenesisCare North Shore ( Site 1103), St Leonards, New South Wales

Blacktown Hospital ( Site 1101), Sydney, New South Wales

Royal Brisbane and Women's Hospital ( Site 1102), Brisbane, Queensland

Epworth Freemasons ( Site 1104), East Melbourne, Victoria

Frankston Hospital ( Site 1105), Frankston, Victoria

Medizinische Universitaet Innsbruck-Univ.-Klinik f. Gynäkologie und Geburtshilfe ( Site 1201), Innsbruck, Tirol

Medizinische Universität Wien ( Site 1202), Wien, Not set

AZ Maria Middelares-IKG ( Site 1305), Gent, Oost-Vlaanderen

UZ Gent-Medical oncology ( Site 1303), Gent, Oost-Vlaanderen

UZ Leuven-Gynecologic Oncology ( Site 1301), Leuven, Vlaams-Brabant

AZ Delta vzw-Oncology ( Site 1302), Roeselare, West-Vlaanderen

CHU UCL Namur/Site Sainte Elisabeth-Trial Office ( Site 1304), Namur, Not set

Hospital São Domingos ( Site 1365), Sao Luis, Maranhao

Centro Oncologico do Triangulo ( Site 1360), Uberlândia, Minas Gerais

Hospital Moinhos de Vento ( Site 1359), Porto Alegre, Rio Grande Do Sul

Instituto Joinvilense de Hematologia e Oncologia ( Site 1353), Joinville, Santa Catarina

Instituto de Ensino e Pesquisa ( Site 1355), Sorocaba, Sao Paulo

Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 1352), Rio de Janeiro, Not set

Hospital Samaritano De Sao Paulo ( Site 1367), Sao Paulo, Not set

A. C. Camargo Cancer Center ( Site 1351), Sao Paulo, Not set

IBCC - Núcleo de Pesquisa e Ensino ( Site 1366), Sao Paulo, Not set

Arthur J.E. Child Comprehensive Cancer Centre ( Site 1413), Calgary, Alberta

Cross Cancer Institute ( Site 1414), Edmonton, Alberta

BC Cancer Vancouver ( Site 1415), Vancouver, British Columbia

Trillium Health Partners - Credit Valley Hospital ( Site 1410), Mississauga, Ontario

CIUSSS- saguenay-Lac-Saint-Jean ( Site 1408), Chicoutimi, Quebec

CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 1405), Montreal, Quebec

Centre Hospitalier de l'Université de Montréal ( Site 1403), Montréal, Quebec

McGill University Health Centre ( Site 1404), Montréal, Quebec

James Lind Centro de Investigacion del Cancer ( Site 1504), Temuco, Araucania

Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1505), Santiago, Region M. De Santiago

Pontificia Universidad Catolica de Chile ( Site 1503), Santiago, Region M. De Santiago

Bradfordhill-Clinical Area ( Site 1501), Santiago, Region M. De Santiago

Second Affiliated hospital of Anhui Medical University-Oncology ( Site 1635), Hefei, Anhui

Beijing Obstetric and Gynecology Hospital ( Site 1653), Beijing, Beijing

Fujian Cancer Hospital-Gynecological Oncology Surgery ( Site 1627), Fuzhou, Fujian

Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 1634), Guangzhou, Guangdong

Sun Yat-sen University Cancer Center ( Site 1604), Guangzhou, Guangdong

Cancer Hospital of Shantou University Medical College ( Site 1642), Shantou, Guangdong

Affiliated Hospital of Guangdong Medical University ( Site 1614), Zhanjiang, Guangdong

Guangxi Medical University Affiliated Tumor Hospital-Gynecological oncology ( Site 1622), Nanning, Guangxi

Hainan General Hospital ( Site 1636), Haikou, Hainan

Harbin Medical University Cancer Hospital-Gynecological Radiotherapy Department ( Site 1652), Harbin, Heilongjiang

Henan Cancer Hospital ( Site 1618), Zhengzhou, Henan

The Second Affiliated Hospital of Zhengzhou University ( Site 1640), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1621), Wuhan, Hubei

Hubei Cancer Hospital-Hubei Cancer Hospital ( Site 1607), Wuhan, Hubei

Xiangya Hospital Central South University-Gynecology ( Site 1603), Changsha, Hunan

Hunan Cancer Hospital ( Site 1623), Changsha, Hunan

Nanjing First Hospital ( Site 1649), Nanjing, Jiangsu

Jiangxi Maternal and Child Health Hospital-Oncology Department ( Site 1625), Nanchang, Jiangxi

LinYi Cancer Hospital-Gastrology department ( Site 1630), Linyi, Shandong

Obstetrics & Gynecology Hospital of Fudan University ( Site 1617), Shanghai, Shanghai

Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 1626), Shanghai, Shanghai

West China Second University Hospital, Sichuan University ( Site 1602), Chengdu, Sichuan

Sichuan Cancer hospital-Oncology ( Site 1650), Chengdu, Sichuan

Xinjiang Medical University Cancer Hospital - Urumqi ( Site 1648), Urumqi, Xinjiang

Yunnan Province Cancer Hospital-Gynecology Department ( Site 1641), Kunming, Yunnan

The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 1609), Hangzhou, Zhejiang

Zhejiang Cancer Hospital-Oncology ( Site 1601), Hangzhou, Zhejiang

Taizhou Hospital of Zhejiang Province ( Site 1633), Linhai, Zhejiang

The First Affiliated Hospital of Wenzhou Medical University ( Site 1615), Wenzhou, Zhejiang

Fakultní Nemocnice Brno-Gynekologicko-porodnicka klinika ( Site 1704), Brno, Brno-mesto

Fakultni nemocnice Ostrava-Gynekologicko-porodnicka klinika ( Site 1703), Ostrava, Moravskoslezsky Kraj

Nemocnice AGEL Novy Jicin a.s.-Oddeleni radioterapie a onkologie ( Site 1706), Nový Jiín, Novy Jicin

Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1702), Olomouc, Olomoucky Kraj

Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 1705), Praha, Praha 2

Fakultni nemocnice Bulovka-Gynekologicko-porodnicka klinika ( Site 1701), Praha, Praha 8

Herlev and Gentofte Hospital-Department of Oncology ( Site 1801), Copenhagen, Hovedstaden

Rigshospitalet-Dept. of Oncology ( Site 1803), Copenhagen, Hovedstaden

Aarhus Universitetshospital, Skejby ( Site 1802), Aarhus, Midtjylland

Tampereen yliopistollinen sairaala ( Site 1901), Tampere, Pirkanmaa

Kuopion Yliopistollinen Sairaala ( Site 1904), Kuopio, Pohjois-Savo

Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1902), Helsinki, Uusimaa

Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1903), Turku, Varsinais-Suomi

Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 2002), Bordeaux, Aquitaine

ROC37 ( Site 2010), Chambray Les Tours, Centre

Centre Armoricain de Radiotherapie Imagerie medicale et Oncologie ( Site 2001), Plerin, Cotes-d Armor

CHU Besançon ( Site 2009), Besançon, Doubs

Institut Claudius Regaud ( Site 2006), Toulouse, Haute-Garonne

Institut Regional du Cancer Montpellier ( Site 2008), Montpellier, Herault

Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 2003), Rennes, Ille-et-Vilaine

Centre Oscar Lambret ( Site 2007), Lille, Nord-Pas-de-Calais

CENTRE LEON BERARD ( Site 2004), Lyon Cedex08, Rhone-Alpes

Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 2005), Paris, Not set

SLK-Kliniken Heilbronn ( Site 2107), Heilbronn, Baden-Wurttemberg

Universitätsmedizin Mannheim-Department of Obstetrics and Gynecology ( Site 2101), Mannheim, Baden-Wurttemberg

MVZ für Hämatologie und Onkologie Ravensburg GmbH - Studienzentrum ( Site 2110), Ravensburg, Baden-Wurttemberg

Universitaetsklinikum Tuebingen ( Site 2111), Tübingen, Baden-Wurttemberg

Agios Andreas Hospital Patras ( Site 2201), Patras, Achaia

Aretaieio Hospital Oncology Unit ( Site 2206), Athens, Attiki

Metropolitan Hospital-2nd Oncology Dept ( Site 2202), Athens, Attiki

Hygeia Hospital ( Site 2204), Marousi, Attiki

Cork University Hospital ( Site 2402), Cork, Not set

Mater Misericordiae University Hospital ( Site 2403), Dublin, Not set

St. James's Hospital-Cancer clinical trials office ( Site 2401), Dublin, Not set

Rambam Health Care Campus-Gyneco-oncology unit ( Site 2502), Haifa, Not set

Edith Wolfson Medical Center ( Site 2501), Holon, Not set

Shaare Zedek Medical Center ( Site 2503), Jerusalem, Not set

Rabin Medical Center ( Site 2505), Petah Tikva, Not set

Sheba Medical Center ( Site 2504), Ramat Gan, Not set

Sourasky Medical Center ( Site 2506), Tel Aviv, Not set

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlin-SSD Oncologia medica Addarii ( Site 260, Bologna, Emilia-Romagna

CRO-IRCCS ( Site 2609), Aviano, Friuli-Venezia Giulia

AOU Policlinico Umberto I ( Site 2606), Roma, Lazio

Istituto Europeo di Oncologia IRCCS ( Site 2607), Milano, Lombardia

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 260, Milan, Lombardia

Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 2610), Rozzano, Milano

Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'O-Day Hospital Oncologico Multidisciplin, Candiolo, Torino

Instituto Tumori Giovanni Paolo II-ONCOLOGIA MEDICA ( Site 2604), Bari, Not set

Azienda Ospedaliera Spedali Civili di Brescia-Obstetrics anf gynecology ( Site 2611), Brescia, Not set

Humanitas San Pio X Hospital ( Site 2614), Milano, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 2, Napoli, Not set

Arcispedale Santa Maria Nuova ( Site 2612), Reggio Emilia, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 2601), Roma, Not set

Ospedale Mauriziano-Ginecologia e Ostetricia ( Site 2608), Torino, Not set

Aichi Cancer Center Hospital ( Site 2714), Nagoya, Aichi

National Hospital Organization Shikoku Cancer Center ( Site 2705), Matsuyama, Ehime

Ehime University Hospital ( Site 2709), Toon, Ehime

Kurume University Hospital ( Site 2703), Kurume, Fukuoka

Gunma Prefectural Cancer Center ( Site 2708), Otashi, Gunma

Hokkaido University Hospital ( Site 2707), Sapporo, Hokkaido

University of Tsukuba Hospital ( Site 2713), Tsukuba, Ibaraki

Iwate Medical University Hospital ( Site 2712), Shiwa-gun, Iwate

Niigata Cancer Center Hospital ( Site 2701), Niigata-shi, Niigata

Saitama Medical University International Medical Center ( Site 2710), Hidaka, Saitama

Shizuoka Cancer Center ( Site 2716), Sunto-gun,, Shizuoka

National Cancer Center Hospital ( Site 2715), Chuo-ku, Tokyo

The Cancer Institute Hospital of JFCR ( Site 2706), Koto, Tokyo

Keio University Hospital ( Site 2702), Shinjuku, Tokyo

National Hospital Organization Kyushu Cancer Center ( Site 2711), Fukuoka, Not set

Kagoshima City Hospital ( Site 2717), Kagoshima, Not set

Osaka International Cancer Institute ( Site 2718), Osaka, Not set

Seoul National University Bundang Hospital-Obstetrics and Gynecology ( Site 3505), Seongnam, Kyonggi-do

Seoul National University Hospital ( Site 3502), Seoul, Not set

Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 3503), Seoul, Not set

Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 3501), Seoul, Not set

Samsung Medical Center ( Site 3504), Seoul, Not set

Pantai Hospital Kuala Lumpur-Cancer Centre ( Site 2803), Kuala Lumpur, Not set

University Malaya Medical Centre ( Site 2801), Kuala Lumpur, Not set

COI Centro Oncologico Internacional S.A.P.I. de C.V. ( Site 2902), Coyoacan, Distrito Federal

Higiea Oncologia ( Site 2905), Mexico City, Distrito Federal

CENTRO MEDICO ZAMBRANO HELLION-Centro de Cáncer de Mama ( Site 2901), San Pedro Garza Garcia, Nuevo Leon

Oncare - Unidad Valle ( Site 2906), San Pedro Garza García, Nuevo Leon

Centro de Investigacion Clinica de Oaxaca ( Site 2907), Oaxaca de Juarez, Oaxaca

Radboudumc-Medical Oncology ( Site 3003), Nijmegen, Gelderland

Amsterdam UMC - locatie VUmc ( Site 3004), Amsterdam, Noord-Holland

Leids Universitair Medisch Centrum-Medical Oncology ( Site 3002), Leiden, Zuid-Holland

Stavanger Universitetssykehus ( Site 3103), Stavanger, Rogaland

Universitetssykehuset Nord-Norge HF ( Site 3101), Tromsø, Troms

Sorlandet Sykehus Kristiansand ( Site 3104), Kristiansand, Vest-Agder

Oslo universitetssykehus, Radiumhospitalet ( Site 3102), Oslo, Not set

Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 3201), Siedlce, Mazowieckie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit, Warszawa, Mazowieckie

Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 3204), Bialystok, Podlaskie

Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie-Oddział Radioterapii i Onkologii Ginek, Poznan, Wielkopolskie

Ad-Vance Medical Research-Research ( Site 3302), Ponce, Not set

Pan American Center for Oncology Trials - Ciudadela ( Site 3301), San Juan, Not set

UPR Comprehensive Cancer Center-Comprehensive Cancer Center Hospital ( Site 3304), San Juan, Not set

National Cancer Centre Singapore-Medical Oncology ( Site 3401), Singapore, Central Singapore

Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 3608), L Hospitalet, Barcelona

Institut Català d'Oncologia (ICO) - Girona-Oncología Médica ( Site 3606), Girona, Gerona

Clinica Universidad de Navarra ( Site 3603), Madrid, Madrid, Comunidad De

Hospital Universitario 12 de Octubre-Medical Oncology ( Site 3607), Madrid, Madrid, Comunidad De

Hospital Universitario La Paz-Oncología Médica ( Site 3604), Madrid, Madrid, Comunidad De

Fundación Instituto Valenciano de Oncología-Oncologico ( Site 3605), Valencia, Valenciana, Comunitat

HOSPITAL CLINICO DE VALENCIA ( Site 3609), Valencia, Valenciana, Comunitat

Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 3602), Barcelona, Not set

Hospital Universitario Reina Sofia-Oncologia Medica ( Site 3601), Cordoba, Not set

Skånes Universitetssjukhus Lund ( Site 3702), Lund, Skane Lan

Karolinska Universitetssjukhuset Solna ( Site 3701), Stockholm, Stockholms Lan

University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 3808), Basel, Basel-Stadt

Kantonsspital Graubünden-Medizin ( Site 3803), Chur, Grisons

Ospedale Regionale Bellinzona e Valli ( Site 3802), Bellinzona, Ticino

Inselspital Bern-Oncology ( Site 3801), Berne, Not set

University Hospitals Sussex NHS Foundation Trust ( Site 4006), East Sussex, Brighton And Hove

Royal Derby Hospital ( Site 4007), Derby, Derbyshire

ROYAL MARSDEN HOSPITAL (CHELSEA)-Gynaecology Research Centre ( Site 4002), London, England

The Royal Cornwall Hospital ( Site 4009), Truro, England

University College London Hospital-Cancer Clinical Trials Unit ( Site 4004), London, London, City Of

Guy's & St Thomas' NHS Foundation Trust-Oncology & Haematology Clinical Trials ( Site 4008), London, London, City Of

Hammersmith Hospital ( Site 4001), London, London, City Of

The Beatson West of Scotland Cancer Centre ( Site 4005), Glasgow, Scotland

Royal Marsden Hospital (Sutton)-Gynaecology Unit ( Site 4010), London, Sutton

The Christie NHS Foundation Trust-Medical Oncology ( Site 4003), Manchester, Not set

Conditions: Endometrial Cancer

Learn More ›

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264

Recruiting

This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors as monotherapy and in combination with fulvestrant with or without BGB-43395, a selective CDK4 inhibitor, in adults with hormone receptor positive (HR+)/human epidermal growth factor rece... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/21/2025

Locations: Hoag Memorial Presbyterian, Newport, California +30 locations

Hoag Memorial Presbyterian, Newport, California

Florida Cancer Specialists and Research Institute, Lake Mary, Florida

Washington University School of Medicine, Saint Louis, Missouri

Titan Health Partners Llc Dba Astera Cancer Care, East Brunswick, New Jersey

Avera Cancer Institue, Sioux Falls, South Dakota

Mary Crowley Cancer Research, Dallas, Texas

Blacktown Cancer and Haematology Centre, Blacktown, New South Wales

Saint Vincents Hospital Sydney, Darlinghurst, New South Wales

Nepean Hospital, Kingswood, New South Wales

Genesiscare North Shore, St Leonards, New South Wales

Princess Alexandra Hospital, Brisbane, Queensland

Cancer Research South Australia, Adelaide, South Australia

Monash Health, Clayton, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing

Beijing Cancer Hospital, Beijing, Beijing

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

Hunan Cancer Hospital, Changsha, Hunan

Shengjing Hospital Affiliated of China Medical University, Shenyang, Liaoning

The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi

Rambam Health Care Center, Haifa, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

National Cancer Center (Korea), Goyangsi, Gyeonggi-do

Seoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Severance Hospital Yonsei University Health System, Seoul, Seoul Teugbyeolsi

Asan Medical Center, Seoul, Seoul Teugbyeolsi

Samsung Medical Center, Seoul, Seoul Teugbyeolsi

The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Not set

Auckland City Hospital, Auckland, Not set

Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer

Learn More ›

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

NCT06695845

Recruiting

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/18/2025

Locations: Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona +13 locations

Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression

Learn More ›

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

NCT06481592

Recruiting

The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.

Gender:

FEMALE

Ages:

Between 18 years and 70 years

Trial Updated:

03/17/2025

Locations: University of Southern California, Los Angeles, California +6 locations

Conditions: Endometrial Cancer

Learn More ›

A Study to Learn About Study Medicine ALTA2618 in Adults with AKT1 E17K-Mutant Solid Tumors

NCT06533059

Recruiting

The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/13/2025

Locations: Research Site, Denver, Colorado +18 locations

Conditions: Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor

Learn More ›

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With Diet in Patients With Advanced/Recurrent Endometrial Cancer

NCT06463028

Recruiting

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/13/2025

Locations: UC San Diego Moores Cancer Center, La Jolla, California +9 locations

Conditions: Endometrial Cancer

Learn More ›

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

NCT05787587

Recruiting

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/11/2025

Locations: The Angeles Clinic, Los Angeles, California +24 locations

Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc

Learn More ›

1 - 12 of 105